Chardan Capital Reiterates Buy Rating for Oculis (NASDAQ:OCS)

Oculis (NASDAQ:OCS - Get Free Report)'s stock had its "buy" rating restated by stock analysts at Chardan Capital in a research note issued on Thursday,Benzinga reports. They presently have a $28.00 price target on the stock. Chardan Capital's target price indicates a potential upside of 58.28% from the company's current price.

A number of other analysts have also issued reports on OCS. Robert W. Baird lifted their price target on Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a research note on Thursday, March 13th. HC Wainwright decreased their target price on shares of Oculis from $30.00 to $29.00 and set a "buy" rating on the stock in a research note on Thursday, March 13th.

Oculis Stock Performance

Oculis stock traded down $0.43 during trading hours on Thursday, hitting $17.69. 8,031 shares of the stock traded hands, compared to its average volume of 46,269. Oculis has a 1 year low of $10.79 and a 1 year high of $23.08. The stock has a market capitalization of $772.38 million, a price-to-earnings ratio of -9.17 and a beta of 0.19. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The firm's 50 day moving average price is $18.76 and its 200-day moving average price is $18.09.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. As a group, equities analysts expect that Oculis will post -2.09 EPS for the current fiscal year.

Institutional Trading of Oculis

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after purchasing an additional 1,800 shares during the last quarter. Bellevue Group AG acquired a new position in shares of Oculis in the fourth quarter valued at approximately $170,000. Bank of America Corp DE increased its position in shares of Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after acquiring an additional 10,667 shares during the period. XTX Topco Ltd purchased a new position in Oculis in the fourth quarter worth approximately $225,000. Finally, Citadel Advisors LLC acquired a new position in Oculis in the fourth quarter valued at $389,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.